Close Menu

Biodesix

While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.

The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.

GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.

Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.

According to a new study, the company returns results for more than 90 percent of its GeneStrat tests within 72 hours and aims to bring that down to 48 hours.

The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.

Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.

The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.

Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.

The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.

Pages

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.